Skip to content
DataLookout
Menu

NCT07114419

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jun 1, 2026 to Jul 6, 2026
    • Secondary endpoints: details revised at 3 of 24 entries
    • Site details revised at 5 of 5 sites
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2025 to Aug 25, 2025
    • Site details revised at 5 of 5 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks
Timeframe: 22 weeks

Secondary (24)

Proportion of subjects with body weight loss ≥ 5%, ≥ 10%, and ≥ 15% from baseline after subcutaneous
Absolute change from baseline in body weight (Kg) after subcutaneous administration for 22 weeks
Changes from baseline in BMI after subcutaneous administration for 22 weeks
Changes from baseline in waist to hip circumference ratio after subcutaneous administration for 22 weeks
Changes from baseline in waist to height ratio after subcutaneous administration of YN-011 for 22 weeks
Show 19 moreShow less
Changes from baseline in systolic and diastolic blood pressure after subcutaneous administration for 22 weeks
Changes from baseline in blood lipids (including TC, TG, LDL-C, and high-density lipoprotein cholesterol [HDL-C]) after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Changes from baseline in glycated hemoglobin (HbA1c) after administration subcutaneous for 22 weeks
Changes from baseline in fasting plasma glucose(FPG) after subcutaneous administration of YN-011 for 22 weeks;
Changes from baseline in fasting insulin after subcutaneous administration of YN-011 for 22 weeks;
Changes from baseline in blood uric acid after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Safety assessment will be conducted throught the study by Incidence of adverse events (AEs) and serious adverse events (SAEs);
Safety assessment will be conducted throught the study by Mental health status via Patient Health Questionnaire-9 (PHQ-9)
Safety assessment will be conducted throught the study by Mental health status via Columbia Suicide Severity Rating Scale (C-SSRS)
Maximum plasma concentration (Cmax) of YN-011 via subcutaneous administration through the study
Timepoint of maximum plasma concentration (Tmax) of YN-011 via subcutaneous administration
Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t) of YN-011 via subcutaneous administration
Elimination half-life (t1/2) of YN-011 via subcutaneous administration
Apparent clearance (CL/F) of YN-011 via subcutaneous administration
Apparent volume of distribution (Vz/F) of YN-011 via subcutaneous administration
Trough concentration (Ctrough) of YN-011 via subcutaneous administration
Incidence of anti-drug antibody (ADA) against YN-011 in serum before and after subcutaneous administration
Incidence of neutralizing antibody (NAb) against YN-011 in serum before and after subcutaneous administration
Changes from baseline in Dual Energy X-ray Absorptiometry [DEXA] data report (DEXA data inculding total fat mass, muscle mass, regional visceral fat mass and total lean body mass) after subcutaneous administration of YN-011

Arms and interventions

Efsubaglutide 20 mg Quaque Week (QW)Experimental

The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 mg, reaching the target dose of 20 mg, the total treatment last for 22weeks.

Efsubaglutide 40 mg QWExperimental

The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg, reaching the target dose of 40 mg, the total treatment last for 22weeks.

Efsubaglutide Alfa 40 mg Q2WExperimental

The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg,when reaching to target dose of 40 mg, administered the drug every 2weeks. the total treatment last for 22weeks.

Efsubaglutide Alfa 80 mg QWExperimental

The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg, reaching the target dose of 80 mg, the total treatment last for 22weeks.

Efsubaglutide Alfa 80 mg Q4WExperimental

The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg → 5 mg → 10 mg → 20 → 40mg→ 80mg,when reaching to target dose of 80 mg, administered the drug every 4weeks. the total treatment last for 22weeks.

Drugs: Efsubaglutide Alfa 20 mg QW, Efsubaglutide Alfa 40 mg QW, Efsubaglutide Alfa 40 mg Q2W, Efsubaglutide Alfa 80 mg QW, Efsubaglutide Alfa 80 mg Q4W

Other: Placebo

Sites

5 sites in 1 country